Exicure

Exicure EBIT per Employee

The EBIT per Employee of Exicure (XCUR) as of Nov 21, 2026 is -1.26 M USD. In the previous year, EBIT per Employee was -1.21 M USD — a change of 4.57% (lower).

EBIT per Employee

-1.26 MUSD

YoY

4.57%

Last updated:

EBIT per Employee of Exicure is 2025 -1.26 M USD. EBIT per Employee of Exicure was 2024 -1.21 M USD. It decreases by 4.57% lower compared to the previous year.

The Exicure EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
-2.76 M USD
Jan 1, 2019
-3.33 M USD
Jan 1, 2020
-3.18 M USD
Jan 1, 2021
-7.82 M USD
Jan 1, 2022
-224,125.00 USD
Jan 1, 2023
-1.87 M USD
Jan 1, 2024
-1.21 M USD
Jan 1, 2025
-1.26 M USD
The Exicure EBIT per Employee history
YEAREBIT per EmployeeYoY
-1.26 MUSD+4.57%
-1.21 MUSD-35.48%
-1.87 MUSD+736.36%
-224,125.00USD-97.13%
-7.82 MUSD+145.92%
-3.18 MUSD-4.44%
-3.33 MUSD+20.64%
-2.76 MUSD+115.97%
-1.28 MUSD-37.00%
-2.03 MUSD+23.38%
-1.64 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exicure Stock analysis

What does Exicure do? Exicure, Inc. generates revenue through the development and commercialization of therapeutic products based on its Spherical Nucleic Acid (SNA) technology. The company focuses on immuno-oncology, genetic disorders, and other indications, with a pipeline including AST-008, XCUR-FXN, and XCUR17. AST-008 is a toll-like receptor 9 agonist designed to activate the innate immune system and induce anti-cancer responses, particularly when combined with checkpoint inhibitors. XCUR-FXN targets Friedreich’s ataxia (FA) in preclinical development, while XCUR17 is an SNA targeting IL-17RA mRNA for inflammatory disorders, Netherton syndrome, and hair loss disorders. The primary buyers of Exicure's products are pharmaceutical companies and healthcare providers seeking innovative treatments for complex conditions. The company's SNA technology enables therapeutic oligonucleotides to work across various cells and tissues, addressing unmet medical needs in immuno-oncology and genetic disorders. Commercial partnerships and licensing agreements are likely key revenue streams, though specific partners are not named in the business description. Exicure's product segments include immuno-oncology (AST-008), genetic disorders (XCUR-FXN), and inflammatory conditions (XCUR17). These segments target patients with specific diseases, such as cancer, Friedreich’s ataxia, and inflammatory disorders, where current treatments are limited. The company's focus on SNA technology differentiates its approach, aiming to unlock new therapeutic possibilities in these areas. Exicure is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exicure stock

EBIT per Employee of Exicure is -1.26 M USD in 2025.

EBIT per Employee of Exicure changed from -1.21 M USD to -1.26 M USD, representing a 4.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Exicure since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Exicure historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Exicure

All Key Metrics — Exicure